The tweet was deleted by the author.
But we saved everything 🙂.
Edgewise Therapeutics has announced plans to release its Q3 2025 financial results on November 6, before the market opens.
The upcoming report will provide insights into the company's recent business performance and strategic highlights. Stakeholders can access the full results on the company's official website.
The forthcoming financial results follow a period of scientific momentum for Edgewise Therapeutics, highlighted by its publication of data from a major Becker Muscular Dystrophy trial, the largest of its kind to date. The company’s continued focus on muscular dystrophy research was also evident during its presentations at the World Muscle Society conference in Vienna, underscoring strategic priorities that may influence upcoming performance disclosures.